TAKING STOCK OF HALF A DECADE OF DRUG POLICY AN EVALUATION OF UNGASS IMPLEMENTATION - EXECUTIVE SUMMARY TAKING STOCK OF HALF A DECADE OF DRUG POLICY AN EVALUATION OF UNGASS IMPLEMENTATION
Marie Nougier,1 Adrià Cots Fernández2 & Dania Putri3
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy Acknowledgements • Heather Haase, International Drug Policy Con- sortium Authors: • Heloisa Broggiato, International Association for • Marie Nougier, Head of Research and Communi- Hospice and Palliative Care cations, International Drug Policy Consortium • Isabel Pereira, Dejusticia • Adrià Cots Fernández, Research and Advocacy Officer, International Drug Policy Consortium • Jamie Bridge, International Drug Policy Consor- tium • Dania Putri, Freelance Consultant • Jérôme Evanno, Parole autour de la Santé The authors wish to thank the following individuals for their valuable comments and contributions: • Katherine Pettus, International Association for Hospice and Palliative Care • Ailish Brennan, Youth RISE • Olivia Rope, Penal Reform International • Ann Fordham, International Drug Policy Consor- tium • Rebecca Schleifer, consultant • Annette Verster, World Health Organization • Ruth Birgin, Women and Harm Reduction Inter- national Network • Coletta Youngers, Washington Office on Latin America & International Drug Policy Consortium • Tania Ximena Pastrana Uruena, International As- sociation for Hospice and Palliative Care • Constanza Sánchez Avilés, ICEERS • Triona Lenihan, Penal Reform International • Dasha Matyushina-Ocheret, consultant, UNAIDS • Zaved Mahmood, Office of the High Commissio- • Dave Bewley-Taylor, Global Drug Policy Observa- tory, Swansea University ner for Human Rights • Deborah Alimi, Univ. Panthéon Sorbonne/Daleth Infographics: research • Juan Fernández Ochoa, International Drug • Diederik Lohman, Open Society Foundations Design: • Giada Girelli, Harm Reduction International • Mathew Birch: whatifweconsulting.com • Gloria Lai, International Drug Policy Consortium Foreword
The United Nations General Assembly Special Ses- sion (UNGASS) on drugs in 2016 and its Outcome Document did not imply a radical change in the in- ternational legal regime on controlled substances, such as cannabis, cocaine or heroin, as it maintained the prohibition of production, distribution and use of these substances, outside medical or scientific use, in spite of the well-documented negative con- sequences of this prohibition on democracy, human rights and public health. That was unfortunate as the world lost a real opportunity to eliminate one of the most substantial drivers of massive human rights violations all over the world in the last dec- ades. However, the UNGASS was not an irrelevant moment either. It was a significant step in the right direction as the Outcome Document proposes im- Rodrigo Uprimny portant elements that allow, or even oblige, States to abandon the most extreme punitive interpreta- of the Outcome Document have been really taken tions of the international legal regime on controlled substances, that have created too much unneces- onboard and implemented by governments and sary suffering in the world. have had positive impacts on the evolution of drug policies. As the reader will see, the balance is mixed. On some aspects, important progress has been The UNGASS Outcome Document rightly introduced a new language and narrative for dealing with drug achieved. For instance, today we have been able to policy, which goes beyond the classic three pillars reduce the strong separation that previously exist- of supply, demand and cooperation of previous UN ed between discussions on drug policy, usually led documents on drug policy. The UNGASS Outcome by the CND in Vienna, and discussions on human Document stresses the need for States to adopt a rights, usually led in Geneva. This sort of Berlin wall public health and development-oriented approach between Geneva and Vienna, so to speak, has fallen; to drug policy, which has to respect human rights, it is more and more accepted that any discussion on and adopt better metrics and indicators to evaluate drug policy has to take into account all the human the impacts and effectiveness of this policy. That rights obligations of States. Conversely, most hu- general orientation of the Outcome Document is man rights bodies have understood that drug policy in itself very important. Besides, in certain aspects, is not a monopoly of the Commission on Narcotic the document goes further and makes more specif- Drugs (CND) or the International Narcotics Control ic and important recommendations. For instance, Board (INCB) in Vienna and that they must monitor instead of promoting punitive approaches in drug any human rights violations associated with drug policies, the Outcome Document urges States to policy. For example, several human rights treaty respect the principle of proportionality when estab- bodies, such as the Committee on Economic, So- lishing criminal drug offences and also to consider cial and Cultural Rights, of which I am member, the alternatives to criminal punishment and prison in Committee on the Rights of the Child or the Human this field. That is not a minor point if we take into Rights Committee, have increasingly made recom- account how, in many parts of the world such as mendations to States to adjust their drug policies to in the United States or all over Latin America, the human rights standards, for instance recommend- enormous increase in incarceration and the unjus- ing the adoption of harm reduction programmes. tified suffering it has caused in the most vulnerable populations has been strongly linked to extremely However, as this report rightly stresses, these punitive versions of drug policy. advances, no matter their importance, have not been able to counterbalance the lack of progress In that context, this very well documented IDPC in other fields of drug policy: or even worst, the report is timely as it evaluates, five years after the regressive steps taken by some countries towards UNGASS, whether these progressive orientations more repressive approaches, including my own
Taking stock of half a decade of drug policy i country, Colombia, in which the government en- visages to re-establish aerial spraying of coca fields with glyphosate, in spite of the recommendations against this measure made by many human rights bodies and most experts in drug policy.
I totally agree with the main conclusions of the re- port: the advances made since the UNGASS for a more humane and democratic drug policy are not only very limited; they also face risks of retrogres- sion. However, this situation should not discourage all persons, organisations or States committed to drug policy reform. On the contrary, we need to maintain our efforts and enthusiasm for drug re- form at the international and national level, making all efforts to ensure that at least all States take seri- ously the commitments they undertook by adopt- ing the UNGASS Outcome Document. We need to continue our efforts to eliminate, or at least, reduce Ann Fordham significantly, the harms and suffering caused by In many respects, the 2016 UNGASS is now widely repressive drug policies. And for that purpose, the considered a high point for progressive drug policy concrete recommendations made by this report are at UN level, with the UNGASS Outcome Document very pertinent as they combine nicely reasonable- heralding a shift in rhetoric towards human rights, ness and courage. health and development. The gains made in the Out- come Document (detailed so well by Rodrigo Uprim- Rodrigo Uprimny ny, with whom I humbly share this foreword) were Professor, National University Colombia hard fought and hard won by several member states Senior researcher at the Center of Studies “Dejusticia” strongly committed to ensuring greater human Member of the UN Committee on Economic, Social and Cul- rights accountability in drug policy. These difficult tural Rights inter-governmental negotiations were accompanied and supported by civil society and, in hindsight, the UNGASS was a galvanising moment for the global drug policy reform movement. Working to leverage the opportunity this high-level moment provided, Almost a decade has passed since Colombia, Mexico the movement became more diverse, visible, coor- and Guatemala called urgently for a UN General As- dinated and vocal than ever before. The Civil Soci- sembly Special Session (UNGASS) on drug policy. At ety Task Force worked tirelessly to ensure that the the General Assembly in 2012, they stated that ‘re- voices, stories and lived experiences of those most vising the approach on drugs maintained so far by affected by drug policy were heard loud and clear in the international community can no longer be post- the UN debates. Working together with progressive poned’ and urged the UN to ‘exercise leadership’ to member states, drug policy reform-oriented civil so- review all the available options, ‘including regulato- ciety managed to gain significant ground on health ry or market measures’, towards a more effective ap- and human rights (including women’s rights) in the proach to address the challenge of drugs. It was not Outcome Document. surprising that this push came from Latin America as the region has borne witness to the unmitigated While there have certainly been important gains devastation of punitive and repressive drug policies over the last five years, and the momentum for – which have ultimately failed to eradicate, or even reforms relating to cannabis (both for medical and reduce, the illegal drug market. for adult non-medical use) and broader decrim- inalisation continues to accelerate, there is still a Five years on, it is important to take stock of what huge chasm between the rhetoric and the reality has been achieved since the UNGASS in 2016, and on the ground as is chronicled in this timely report. to see if, indeed, the urgent call for a revised ap- Meaningful reforms have yet to materialise is most proach was realised. parts of the world and many governments remain ii Taking stock of half decade of drug policy wedded to draconian measures with catastrophic policy responses. Together with the seminal 2018 impacts on communities. Civic space is under pres- UN Common Position on drug-related matters, sure at all levels as authoritarian governments seek these recommendations set up a blueprint for to shut down dissident voices and undermine hu- drug policy reform for the next five years. However man rights defenders. the option of ‘regulatory’ approaches was still con- sidered a step too far and was cautiously avoided This year also marks 50 years since US President in both documents – although reforms on the Nixon declared the ‘war on drugs’ – coining a phrase ground continue regardless. that has sadly become emblematic of so much needless human suffering in the futile pursuit of a There is still hope that a decade after the 2016 UN- ‘drug-free society’. The world cannot suffer another 50 years of failed and damaging drug policies. Civil GASS, the ‘revised approach’ called for at the very society must continue to lead the way, fighting to inception of this whole process will truly be under- maintain civil space, speaking truth to power, lifting way, and that governments will have the courage to up the voices of the most affected and challenging implement much needed and urgent reforms put- harmful drug policies and approaches. ting human rights, social justice, racial justice and gender equality at the centre of drug policies. In addition to outlining progress, or lack thereof, this report also provides clear recommendations Ann Fordham on how the global community can truly centre IDPC Executive Director health, human rights and development into drug
Taking stock of half decade of drug policy Taking stock of half a decade of drug policy 5 Acronyms
AIDS Acquired Immune Deficiency Syndrome ARQ Annual Report Questionnaire ATS Amphetamine Type Stimulants CCDC Compulsory drug detention centre CCPCJ Commission on Crime Prevention and Criminal Justice CND Commission on Narcotic Drugs CSTF Civil Society Task Force DCR Drug consumption room ECDD Expert Committee on Drug Dependence EU European Union HIV Human Immunodeficiency Virus ICEERS International Center for Ethnobotanical Education, Research, and Service IDPC International Drug Policy Consortium INCB International Narcotics Control Board LGBTQ+ Lesbian, Gay, Bisexual, Transgender and Queer and others NGO Non-Governmental Organisation NPS New Psychoactive Substances NSP Needle and Syringe Programme OAT Opioid Agonist Therapy OHCHR Office of the High Commissioner for Human Rights OST Opioid Substitution Therapy PNIS Programa Nacional Integral de Sustitución de Cultivos Ilícitos (National Comprehensive Program for the Substitution of Illicit Crops) SDGs Sustainable Development Goals SSDP Students for Sensible Drug Policy TNI Transnational Institute UK United Kingdom UN United Nations UNAIDS Joint United Nations Programme on HIV/AIDS UNDP United Nations Development Programme UNDRIP UN Declaration on the Rights of Indigenous Peoples UNGASS United Nations General Assembly Special Session UNICEF United Nations Children’s Fund UNODC United Nations Office on Drugs and Crime USA United States of America WHO World Health Organization
6 Taking stock of half decade of drug policy AIDS Acquired Immune Deficiency Syndrome Table of contents ARQ Annual Report Questionnaire Foreword 1 ATS Amphetamine Type Stimulants Acronyms 6 CCDC Compulsory drug detention centre Executive summary 7 CCPCJ Commission on Crime Prevention and Criminal Justice CND Commission on Narcotic Drugs 1. Introduction 11 CSTF Civil Society Task Force 2. A public health approach 15 DCR Drug consumption room 2.1 Harm reduction 16 ECDD Expert Committee on Drug Dependence Drug-related harm and deaths 16 EU European Union Access to harm reduction services 18 HIV Human Immunodeficiency Virus 2.2 Drug dependence treatment 21 ICEERS International Center for Ethnobotanical Education, Research, and Service The global stagnation of treatment: Scarcity and lack of diversity 21 IDPC International Drug Policy Consortium Limited room for innovation 23 INCB International Narcotics Control Board Involuntary treatment and human rights violations 23 LGBTQ+ Lesbian, Gay, Bisexual, Transgender and Queer and others NGO Non-Governmental Organisation 2.3 Access to controlled substances for medical and scientific use 25 NPS New Psychoactive Substances Updating lists and guidelines on essential medicines 26 NSP Needle and Syringe Programme The global effort to remove barriers to access and address global disparity 27 OAT Opioid Agonist Therapy December 2020: UN symbolically recognises the medicinal value of cannabis 28 OHCHR Office of the High Commissioner for Human Rights 3. A development-oriented approach 31 OST Opioid Substitution Therapy 3.1 Moving towards a sustainable development rhetoric 32 PNIS Programa Nacional Integral de Sustitución de Cultivos Ilícitos (National Comprehensive 3.2 … With limited progress on the ground 34 Program for the Substitution of Illicit Crops) 3.3 Complex realities call for comprehensive and socially just models of sustainable development 36 SDGs Sustainable Development Goals SSDP Students for Sensible Drug Policy 3.4 Cultivation, drug control and environmental degradation 38 TNI Transnational Institute 3.5 Expanding development-oriented strategies to urban areas 39 UK United Kingdom 3.6 Looking towards long-term, sustainable development 40 UN United Nations 4. An improved articulation of drug control and human rights 41 UNAIDS Joint United Nations Programme on HIV/AIDS 4.1 Women 44 UNDP United Nations Development Programme Access to health services for women who use drugs 44 UNDRIP UN Declaration on the Rights of Indigenous Peoples Women incarcerated for drug offences 46 UNGASS United Nations General Assembly Special Session Women in cultivation areas 48 UNICEF United Nations Children’s Fund 4.2 Children and young people 50 UNODC United Nations Office on Drugs and Crime The health dimension: Prevention, treatment, and harm reduction for children and youth 50 USA United States of America WHO World Health Organization The impact of drug law enforcement on children 52 4.3 Criminal legal reform 54 Addressing the over-incarceration of people for drug offences 54 Ensuring more proportionate penalties for drug offences 56 Ending the overreliance on pretrial detention 56 Decriminalising drug use and possession 57 Promoting alternatives to incarceration 58 The right to a fair trial 59
Taking stock of half decade of drug policy Taking stock of half a decade of drug policy 7 Marginalised people in the criminal legal system 60 Widespread impunity for serious rights violations 61 Prohibition of arbitrary arrest and detention, and of torture and other cruel, inhuman 61 or degrading treatment or punishment 4.4 Indigenous and cultural rights 63 5. Ensuring the meaningful participation of civil society, especially affected communities 67 5.1 Civil society and community engagement in global drug policy debates 68 5.2 Civil society and community involvement in service delivery and national-level advocacy 70 5.3 Civil society and community mobilisation at times of COVID-19 72 5.4 Civil society and the private sector 73 6. Improving UN agency collaboration and coordination 75 6.1 The UN System Common Position on drug-related matters 77 6.2 Integrating other UN entities within the Vienna debates 78 6.3 The other side of coherence: Drug policies outside Vienna 79 7. The quest for new indicators to evaluate drug policy success 81 7.1 A revised Annual Report Questionnaire (ARQ) 82 7.2 The UN implementation Task Team 84 7.3 A key role for civil society 85 8. Conclusions and recommendations 87 8.1 Recommendations for global drug policy reform 89 8.2 Recommendations for national drug policy reform 90 Ensuring a public health approach to drug policy 90 Ensuring a development-oriented approach to drug policy 90 Ensuring a human rights-based approach to drug policy 90 Ensuring the meaningful participation of civil society in drug policy 91 Improving data collection, monitoring and evaluation of drug policies 91 Endnotes 92
Boxes
Box 1 Mexico’s ongoing lack of access to prescription opioids for the poor 27 Box 2 Civil society led advocacy for access to medicinal cannabis in Indonesia 29 Box 3 The case of trans women deprived of liberty 49 Box 4 Article 33 of the Convention on the Rights of the Child 51 Box 5 Mobilising young people for evidence-based eath penalty for drug offences 52 Box 6 The silence of the UNGASS: The case of the death penalty for drug offences 58 Box 7 Protecting the right to personal autonomy and self-determination for people who use drugs 64 in Mexico and South Africa Box 8 Advocating for the cultural rights of Andean migrants in Europe 64
8 Taking stock of half a decade of drug policy Executive Summary
April 2021 marks the five-year anniversary of the A development-oriented approach 2016 United Nations General Assembly Special Ses- There has been a welcome shift in the global dis- sion (UNGASS) on drugs. This report aims to take course on development and drug policies since stock of progress made on the implementation of 2016, from an eradication-focused approach to a the operational recommendations included in the greater emphasis around sustainable development UNGASS Outcome Document. Using desk-based re- and livelihoods – linking drug policies to the Sustain- search, and drawing on data and analysis from UN re- able Development Goals (SDGs). Nevertheless, these ports, academia, civil society and the community, the new commitments have yet to materialise at country report focuses on six critical areas: public health, de- level. In most contexts, crop eradication campaigns velopment, human rights, civil society engagement, have continued, destroying livelihoods and the en- UN agency collaboration and cooperation, and drug vironment, and fuelling human rights abuses, social policy evaluation. While some progress has been un- deniably made, the research gathered in this report unrest and violence, principally on the world’s poor- shows that in the last five years the gap between pol- est farmers. In areas where alternative development icy commitments on paper and meaningful change programmes are in place, inadequate sequencing or on the ground has continued to widen. implementation, lack of access to infrastructure and legal markets, and the expansion of extractive in- A public health approach dustries have often left farmers with no other choice than to continue cultivating illegal plants. World Health Organization (WHO) data shows an in- crease in the number of people who died of ‘drug use disorders’ from 154,811 in 2015 to 181,758 in 2019, In urban areas, involvement in the supply side of the with the total number of deaths associated with drug illegal drug market, such as selling or transporting use (including those related to HIV and hepatitis C) drugs, is predominantly attributed to poverty, as estimated at 585,000 in 2017. People who inject drugs well as racial, ethnic, class, and gender inequalities, remain particularly vulnerable to HIV, hepatitis C and all of which are exacerbated by punitive drug laws. tuberculosis infection, while overdose deaths have There again, criminalisation and incarceration con- reached record highs. The continued lack of access to tinue to be the dominant approach, thus undermin- harm reduction and evidence-based treatment ser- ing the sustainable urban development approach vices is one of the main reasons for this trend, with lit- needed to address such inequalities. tle progress made since 2016. The ongoing criminali- A human rights approach sation, stigmatisation and acts of intimidation, abuse, ill-treatment and torture against people who use Progress has been made in the recognition of the drugs are also major contributing factors. Restrictions multiple human rights abuses committed in the due to the COVID-19 pandemic have further limited name of drug control by UN human rights bodies, availability and access – although in some contexts as well as at the UN in Vienna. However, the shift COVID-19 has led to the development of innovative in rhetoric since the 2016 UNGASS has not led to harm reduction approaches, and to much-needed meaningful change for communities on the ground. flexibility in the rules for accessing treatment. Women continue to be disproportionately im- Meanwhile, five billion people around the globe pacted by punitive drug control measures. Wom- have little to no access to controlled medicines for en who use drugs are particularly vulnerable to pain relief, anaesthesia and the treatment of drug health harms, but their access to gender-sensitive dependence, mainly due to unnecessary restrictive harm reduction and treatment services has not regulations. The problem predominantly affects the improved over the past five years. Stigma, crimi- world’s poorest, especially in the Global South. This nalisation, fear of loss of child custody and other is despite advances in global commitments to ad- punitive measures play a major role in deterring dress this ongoing crisis. The long-overdue recogni- women from accessing the services that do exist. tion of the medicinal value of cannabis by the UN in As was the case five years ago, the proportion of December 2020 is a small, but significant, step in the women incarcerated for drug offences remains right direction. high at 35% of women deprived of their liberty
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy 9 globally. In illegal crop cultivation areas, women’s Ensuring the meaningful participation lives are marked by various forms of discrimina- of civil society, especially affected tion, isolation and marginalisation – which are not communities adequately addressed in drug policy and alterna- tive development programmes. Although civil society involvement in global decision making processes on drugs has improved in some Children and young people remain a main target respects since the UNGASS, civil society continues to – and justification for – punitive drug control ap- be left out of most local, national and global policy proaches. Health measures for young people often making processes, especially those whose lives are consist of ‘just say no’ prevention campaigns, forced most affected by drug policies. The COVID-19 pan- urine testing and police searches at school, neglect- demic and associated government restrictions have ing much-needed access to age-sensitive harm re- further restricted civil society space at all levels of duction services. Drug law enforcement measures governance. Nonetheless, civil society organisations have also resulted in a range of human rights vio- have continued to mobilise, both to protect and lations on children and youth. The killing or incar- claim their human rights, and to provide life-saving ceration of parents and caregivers in drug control access to key services for people on the ground. operations have had devastating impacts on their children, including distress, traumatic separation, Improving UN agency collaboration and loss of income, difficulties at school and bullying. coordination The imposition of a criminal record on a child leads Some undeniable progress has been made to im- to reduced prospects for access to higher education prove UN system-wide coherence on drug policy and employment. issues, including with the launch of the Internation- Punitive drug control has also had a major impact al Guidelines on Human Rights and Drug Policy and on the criminal legal system, contributing to over- the adoption by all UN agencies of the UN System crowding through the ongoing use of pretrial de- Common Position on drug-related matters. The reg- tention, mandatory minimum and disproportionate ular engagement of UN human rights, health and sentencing, delays in court decisions, limited access development agencies in Vienna-based debates to legal aid, and lack of access to meaningful alter- – and increased visibility of drug policy issues in natives to prison and punishment. As a result, one their overall work – have also been a positive devel- in five people in prison worldwide continue to be opment since 2016. Nevertheless, much remains to incarcerated for drug offences, 550,000 of whom for be done, in particular with regards to the dissemina- simple drug use – with devastating consequences tion and operationalisation of the Common Position on prison overload and conditions of detention, es- by its implementation Task Team. pecially in the context of the COVID-19 pandemic. Drug law enforcement and criminal sanctions have Evaluating drug policy success disproportionately affected women and people Since the UNGASS, efforts have been made to im- belonging to racial and ethnic minorities. Although prove the way the UN collects data on drug policy. some measures have been undertaken to decrim- A revised Annual Reports Questionnaire (ARQ) was inalise drug use, ensure more proportionate sen- adopted in 2020, which provides an improved tool tencing and offer alternatives to incarceration, the to measure drug policy success, notably in terms impacts on overall levels of incarceration have been of access to health services and use of alternatives minimal. to incarceration, with gender-disaggregated data. In parallel, survivors of human rights violations Nonetheless, the tool does not go far enough in committed in the name of drug control have had truly assessing the human rights and development no access to effective remedy. This is despite the impacts of drug policies and remains overly fo- acts of torture and cruel, inhuman and degrading cused on assessing the overall scale of the illegal treatment or punishment against people involved drug market. Although the Task Team in charge of in illegal drug activities and people who use drugs, implementing the UN System Common Position including abuses in compulsory drug detention could play a critical role in collecting much-needed centres and private treatment facilities, the ongoing drug-related data from other parts of the UN, its role use of corporal punishment, and police brutality, in this domain has yet to materialise. The current UN among others. Finally, no meaningful change has data collection mechanism on drugs also fails to rec- occurred since the UNGASS to protect the rights of ognise the critical role played by civil society in this indigenous groups, in line with the UN Declaration area, despite efforts made by various NGOs to fill the on the Rights of Indigenous Peoples. gap in data collection, monitoring and evaluation.
10 Taking stock of half a decade of drug policy Recommendations for the next decade of drug policy
• Ensure the meaningful participation of civil ethnic and racial minorities and indigenous society, in particular affected communities, groups. in local, national, regional and internation- • Review drug laws and policies to remove all al drug policy making, implementation, punishments for drug use and possession for monitoring and evaluation, and actively personal use, ensure proportionate penalties promote civil society space via institutional- and sentencing practices, use meaningful ised channels for participation, political and alternatives to incarceration and punishment financial support. and ensure access to legal aid – with the goal • Ensure the wide dissemination and opera- of using prison only as a means of last resort. tionalisation of the UN System Common Po- • Abolish the death penalty in all circum- sition and a stronger, adequately funded, role stances, and ensure that penalties for those for its implementation Task Team, including in currently on death row are commuted to a data collection. sentence commensurate with the severity of • Improve access to, and sustainable funding the offence. for, harm reduction, treatment and controlled • Ensure timely access to justice and reparations medicines, with specific emphasis on wom- for survivors of human rights violations com- en, LGBTQ+ communities, youth, ethnic mi- mitted in the name of drug control, such as norities and people deprived of their liberty extrajudicial executions, police brutality, and – including amidst the COVID-19 pandemic. abuses committed in public and private drug Ensure that all health interventions are strictly treatment centres. voluntary, based on scientific evidence, and • Reduce the prominence of indicators focusing respectful of the rights and dignity of those on the overall scale of and flows within the illegal wishing to access them. drug market, and focus instead on more mean- • Adopt development-oriented drug policies ingful indicators to measure progress towards that truly address the poverty, marginalisation, protecting health, improving human rights, wel- lack of access to land and basic services, in both fare, gender equality, and reducing levels rural and urban areas, including for women, of violence.
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy 11 Notes
12 Taking stock of half a decade of drug policy PartPart 21 Introduction
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy 13 19 April 2021 marks the five-year anniversary of the the world has been on the rise’9), but also harmful adoption of the Outcome Document of the United as it has justified widespread human rights abuses Nations General Assembly Special Session (UN- committed in the name of drug control. Further- GASS) on drugs.5 Calls to hold a Special Session on more, critical issues failed to be incorporated in drug-related issues had originated from one of the the Outcome Document, including the need to regions most affected by repressive drug policies abolish the death penalty, the differentiated im- and their consequences on security, development, pacts of drug control on LGBTQ+ communities, health and human rights issues: Latin America, the exploration of legal regulation models for cer- following a joint declaration from the Presidents tain drugs, or the unequivocal support for a harm of Colombia, Guatemala and Mexico.6 The UNGASS reduction approach.10 took place at a time of unprecedented calls for Nonetheless, the UNGASS Outcome Document drug policy change at global and national level. In constitutes a milestone in global drug policy. Since addition, the fact that the Special Session was held then, various member states have pushed back soon after the adoption of the 2030 Agenda for against the Outcome Document, seeking to down- Sustainable Development influenced the overall play it by promoting instead the 2009 Political Dec- shift in narrative and encouraged member states laration. This was made particularly clear during the to adopt a broader development perspective on 2019 Ministerial Segment and the negotiation of its drug control. Ministerial Declaration,11 which refers to all global Soon after the UNGASS, reform-minded NGOs and commitments adopted since 2009. 12 In this context, policy makers alike recognised the major steps for- it is critical that the Outcome Document remains ward made at the Special Session, as well as within prominent in international drug policy debates. its Outcome Document, in particular in the promo- Paragraph 9 of the UNGASS Outcome Document tion of drug policies better aligned with the promo- resolves to: tion of health, human rights and development. The Special Session was a catalyst moment to promote ‘take the steps necessary to implement the more coherence within the UN system in the area above-listed operational recommendations, in of drug policy, as an unprecedented number of close partnership with the United Nations and oth- UN agencies engaged in the debates.7 Another er intergovernmental organizations and civil socie- welcome aspect of the UNGASS was the broad ac- ty, and to share with the Commission on Narcotic knowledgement that civil society has a central role Drugs, as the policymaking body of the United to play in the design and implementation of drug Nations with prime responsibility for drug con- policies at global level.8 trol matters, timely information on progress made in the implementation of these recommendations’ Yet, in the immediate aftermath of the UNGASS, (emphasis added). many drug policy reform advocates had a feeling of disappointment over the final iteration of the Half a decade after the adoption of the Outcome document, which had taken over two years for Document, it is therefore time to take stock of member states to negotiate. Among other con- ‘progress made’ since April 2016 on the imple- cerns, the Outcome Document reiterated the key mentation of the document’s many recommenda- objective for the international community to pro- tions. In February 2017, in an effort to reflect on mote a ‘society free of drug abuse’. This objective, the progressive aspects of the UNGASS Outcome included in some form in all UN high-level political Document, IDPC produced an analysis of the most documents on drugs, has not only been unrealistic useful elements of the Outcome Document that (in 2020, the United Nations Office on Drugs and civil society could use for drug policy advocacy Crime (UNODC) concluded that ‘Drug use around in the years to come, in the briefing paper ‘How
14 Taking stock of half a decade of drug policy to capitalise on progress made in the UNGASS This analysis is all the more urgent as drug policy Outcome Document: A guide for advocacy’. The discussions have shifted significantly over the past briefing focused on four overarching issues: pub- five years, in particular on issues associated with hu- lic health, development, human rights and civil man rights and gender, and as health priorities have society engagement.13 shifted drastically to respond to the COVID-19 pan- Building upon our 2017 briefing paper, this report demic. The report is based on desk-based research aims to analyse what progress has been made to using data from UN reports, academia, as well as date in the implementation of the recommenda- civil society and community research. It also seeks tions included the UNGASS Outcome Document to give a voice to the many communities that are in these four critical areas – as well as on two ad- most affected by drug policies around the world, ditional themes: the improvement of UN agency via quotes and testimonies that truly reflect the collaboration and cooperation, and the consider- impacts of current drug policies on the ground – ation of how to evaluate success in drug policy. beyond data and numbers.
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy 15 Notes
16 Taking stock of half a decade of drug policy PartPart 22 A public health approach
Taking stock of half a decade of drug policy Taking stock of half a decade of drug policy 17 2.1 Harm reduction
C) at 585,000 (2017 data).17 Half of those deaths Relevant UNGASS recommendations: were ‘attributed to liver cancer, cirrhosis and other • Paragraph 1.m ‘Promote (…) the use of opi- chronic liver diseases related to hepatitis C’.18 oid receptor antagonists such as naloxone The UNODC, WHO, Joint United Nations Programme to reduce drug-related mortality’. on HIV and AIDS (UNAIDS) and World Bank esti- • Paragraph 1.o. ‘Consider (…) effective meas- mated the prevalence of hepatitis C among people ures aimed at minimizing the adverse public who inject drugs worldwide to be 48% in 2018, rep- health and social consequences of drug abuse, resenting 5.5 million people aged 15-64.19 A 2019 including appropriate medication-assisted therapy programmes, injecting equipment study published in The Lancet also found that 39% programmes, as well as antiretroviral therapy of new hepatitis C infections are estimated to be and other relevant interventions that prevent among people who inject drugs.20 the transmission of HIV, viral hepatitis and other People who inject drugs represented 10% of all new blood-borne diseases associated with drug use, 21 as well as consider ensuring access to such inter- HIV infections in 2019, a 2% increase from 2016 22 23 ventions, including in treatment and outreach data, and representing 1.4 million people. This services, prisons and other custodial settings number rises dramatically in certain regions, espe- (…)’. cially in Eastern Europe and Central Asia and the Middle East and North Africa, where 48% and 43% of all new HIV infections respectively are associated Drug-related harm and deaths with injecting drug use. In 2019, UNAIDS estimated that a person who injects drugs is 29 times more In 2016, UN member states committed to ‘pro- likely to acquire HIV than a person who does not.24 moting the health, welfare and well-being of all individuals, families, communities and society as a According to the WHO, people who use drugs ‘are whole’ (paragraph 1). Three years later, the interna- at increased risk of [tuberculosis], regardless of HIV tional community took stock of progress made over status’.25 People living with HIV who inject drugs are the past decade in international drug policy at the two to six times more likely to develop tuberculosis, 2019 Ministerial Segment held in Vienna. Two of the and tuberculosis is the leading cause of mortality ‘persistent and emerging challenges’ identified in among people who inject drugs and who are living the resulting Ministerial Declaration were that ‘the with HIV.26 rate of transmission of HIV, the hepatitis C virus and People who use drugs in prison are particularly vul- other blood-borne diseases associated with drug nerable to health-related harms. According to UN- use, including injecting drug use in some countries, AIDS, ‘recent incarceration is associated with an 81% remains high’, and that ‘the adverse health conse- and 62% increased likelihood of HIV infection and quences of and risks associated with new psychoac- hepatitis C infection, respectively’ among people tive substances have reached alarming levels’.14 who inject drugs.27 Similarly, the risk of contracting Indeed, a World Health Organization (WHO) com- tuberculosis in prison is 23 to 50 times that of the parison of the number of people who died as a re- general population, with the stigmatisation and sult of ‘drug use disorders’ between 2015 and 2019 criminalisation of people who use drugs contribut- 28 showed that this number increased from 154,81115 ing to higher rates of tuberculosis. to 181,758.16 Quoting data from the Global Burden According to the 2020 World Drug Report, the num- of Disease, the 2020 World Drug Report estimates ber of drug overdose deaths remains at record high the total number of deaths associated with drug use levels.29 The USA reported a total of 67,367 drug (including those associated with HIV and hepatitis overdose deaths in 2018 (latest available data)30
18 Taking stock of half a decade of drug policy